protocol approval SOP – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Mon, 18 Aug 2025 02:13:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for REB Requirements and Reporting Timelines https://www.clinicalstudies.in/sop-for-reb-requirements-and-reporting-timelines/ Mon, 18 Aug 2025 02:13:00 +0000 https://www.clinicalstudies.in/sop-for-reb-requirements-and-reporting-timelines/ Read More “SOP for REB Requirements and Reporting Timelines” »

]]> SOP for REB Requirements and Reporting Timelines

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/reb-requirements-and-reporting-timelines”
},
“@id”: “https://www.clinicalstudies.in/reb-requirements-and-reporting-timelines”,
“headline”: “SOP for REB Requirements and Reporting Timelines”,
“name”: “SOP for REB Requirements and Reporting Timelines”,
“description”: “Comprehensive SOP describing Research Ethics Board submission and reporting requirements, including initial submissions, continuing reviews, amendments, safety updates, and communication logs to ensure ethics oversight compliance.”,
“keywords”: “REB requirements SOP, ethics board reporting timelines, REB submission SOP, REB approval workflow, ethics compliance Canada, investigator responsibilities REB, trial amendments ethics board, REB notification procedures, protocol approval SOP, REB communication log, safety reporting REB, informed consent REB review, site initiation ethics board, REB correspondence SOP, REB oversight compliance, ethics committee reporting SOP, REB inspection readiness, REB documentation retention, REB approvals and renewals, SOP for clinical research ethics, REB report deadlines, REB continuing review SOP, REB communication management, trial governance SOP ethics, REB sponsor obligations”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

REB Requirements and Reporting Timelines SOP

Department Clinical Research
SOP No. CS/HC-SAF/166/2025
Supersedes N.A.
Page No. 1 of 20
Issue Date 28/08/2025
Effective Date 05/09/2025
Review Date 05/09/2027

Purpose

This SOP defines the process for submitting documents, obtaining approvals, and reporting to Research Ethics Boards (REBs) to ensure compliance with Division 5 and ICH-GCP requirements. It establishes timelines, documentation standards, and communication pathways to safeguard participant rights and maintain regulatory oversight throughout the clinical trial lifecycle.

Scope

This SOP applies to all REB submissions related to clinical trials sponsored or overseen by the organization. It covers initial submissions, continuing reviews, amendments, safety updates, annual renewals, study termination, and urgent notifications (e.g., protocol deviations impacting subject safety). It is applicable to investigators, site staff, sponsors, regulatory affairs, and clinical research teams operating in compliance with GCP.

Responsibilities

  • Principal Investigator (PI): Submits initial and ongoing documentation to the REB, responds to REB queries, and ensures site staff compliance.
  • Clinical Research Coordinator (CRC): Prepares submissions, maintains correspondence logs, and tracks timelines for continuing reviews and renewals.
  • Regulatory Affairs (RA): Provides regulatory documentation, ensures alignment of REB submissions with CTA dossier, and files acknowledgments in TMF.
  • Sponsor/Clinical Project Manager: Oversees REB submission strategy across multiple sites, monitors compliance with timelines, and supports corrective actions.
  • Quality Assurance (QA): Audits REB submission packages and correspondence to ensure completeness, accuracy, and inspection readiness.

Accountability

The Principal Investigator is accountable for ensuring timely submission of ethics documents and adherence to REB reporting requirements. The Head of Clinical Research is accountable for oversight and compliance monitoring across studies.

Procedure

1. Initial REB Submission

  1. Compile protocol, Investigator’s Brochure (IB), informed consent forms (ICFs), recruitment materials, and relevant safety data.
  2. Submit documentation to REB prior to trial initiation and maintain an indexed REB submission file.
  3. Record REB approval number, validity dates, and conditions of approval in REB Approval Log.

2. Amendments

  1. Submit substantial protocol amendments, revised ICFs, and updated safety data to REB before implementation, unless urgent safety measures are required.
  2. Maintain Amendment Log tracking submission dates, approvals, and site-level implementation status.

3. Continuing Review and Renewals

  1. Prepare annual progress reports summarizing enrollment, safety events, deviations, and benefit-risk updates.
  2. Submit renewal packages at least 30 days before REB approval expiry to ensure uninterrupted trial conduct.

4. Safety Reporting

  1. Report unanticipated problems involving risks to participants to REB within 7 days of awareness.
  2. Submit expedited reports for SUSARs and periodic updates summarizing safety data.

5. Study Closure

  1. Submit final report including enrollment summary, outcomes, and CSR reference to REB after trial completion or early termination.
  2. Ensure documentation of REB closure acknowledgment in TMF and ISF.

6. Documentation and Record-Keeping

  1. Maintain REB Submission Log, Amendment Log, Safety Reporting Log, and Communication Log in TMF.
  2. Archive all REB approvals, correspondence, and supporting documents per retention timelines.

Abbreviations

  • REB: Research Ethics Board
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • CTA: Clinical Trial Application
  • CSR: Clinical Study Report
  • SUSAR: Suspected Unexpected Serious Adverse Reaction
  • TMF: Trial Master File
  • QA: Quality Assurance

Documents

  1. REB Submission Log (Annexure-1)
  2. Amendment Log (Annexure-2)
  3. REB Communication Log (Annexure-3)

References

Version: 1.0

Approval

Prepared By Checked By Approved By
Name: Rajesh Kumar
Date: 20/08/2025
Signature: __________		 Name: Sunita Reddy
Date: 22/08/2025
Signature: __________		 Name: Dr. Meera Iyer
Date: 28/08/2025
Signature: __________

Annexures

Annexure-1: REB Submission Log

Date Submission Type Protocol No. REB Reference Status Submitted By
05/08/2025 Initial Submission ONC-2025-02 REB-1234 Approved Rajesh Kumar

Annexure-2: Amendment Log

Date Amendment Description Status Submitted By
18/09/2025 Amendment 1 Revised inclusion/exclusion criteria Under Review Sunita Reddy

Annexure-3: REB Communication Log

Date Mode Subject Action Taken Responsible
20/08/2025 Email REB Query — Safety data clarification Response sent with updated SAE narrative Rajesh Kumar

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
28/08/2025 1.0 Initial issue: REB submission and reporting framework established. New SOP developed for Division 5 compliance. Head, Clinical Research

For more SOPs visit: Pharma SOP.

]]> Review and Approval Workflow for Protocol Documents in Clinical Trials https://www.clinicalstudies.in/review-and-approval-workflow-for-protocol-documents-in-clinical-trials/ Thu, 10 Jul 2025 22:21:02 +0000 https://www.clinicalstudies.in/review-and-approval-workflow-for-protocol-documents-in-clinical-trials/ Read More “Review and Approval Workflow for Protocol Documents in Clinical Trials” »

]]> Review and Approval Workflow for Protocol Documents in Clinical Trials

How to Manage the Review and Approval Workflow for Clinical Trial Protocols

In clinical trials, the protocol is a regulatory cornerstone. It defines the trial design, objectives, safety parameters, and operational details. Ensuring the protocol is reviewed and approved with precision is essential to align stakeholders, minimize risks, and comply with regulatory expectations like USFDA and ICH-GCP guidelines.

This tutorial provides a step-by-step workflow for the review and approval of clinical trial protocol documents, from drafting through final sign-off. It ensures cross-functional collaboration, accurate version control, and regulatory compliance.

Understanding the Protocol Review and Approval Lifecycle:

The protocol document lifecycle involves several stages: drafting, internal scientific review, cross-functional feedback, QC editing, final approval, and regulatory submission. Each stage has defined responsibilities and timelines to ensure quality and efficiency.

The standard protocol approval process can be broadly broken into the following stages:

  1. Initial Drafting
  2. Internal Functional Review
  3. Consolidation of Comments
  4. Medical and Regulatory Review
  5. Quality Control Check
  6. Version Control and Sign-off
  7. Final Approval and Archival

Stage 1: Initial Drafting of the Protocol

The medical writing team, in collaboration with clinical, regulatory, and statistical leads, develops the initial draft. Inputs are taken from the protocol synopsis, therapeutic area experts, and available preclinical/clinical data.

  • Use a standardized Pharma SOP template or protocol writing template
  • Include key sections per ICH E6 and SPIRIT guidelines
  • Ensure the scientific rationale is robust and ethical considerations are addressed

Tools like electronic authoring platforms or cloud-based writing systems can facilitate collaborative drafting.

Stage 2: Internal Functional Area Review

The drafted protocol is circulated among stakeholders for functional review. Reviewers typically include:

  • Clinical Research and Medical Affairs
  • Biostatistics and Data Management
  • Regulatory Affairs
  • Drug Safety and Pharmacovigilance
  • Clinical Operations
  • Quality Assurance

Each stakeholder ensures that their respective domain requirements are addressed, such as dosing accuracy, data capture feasibility, safety monitoring, and regulatory alignment.

Stage 3: Consolidation and Resolution of Comments

The medical writer or designated protocol owner consolidates all comments into a structured matrix. Comments are categorized as:

  • Editorial
  • Scientific/Content Related
  • Regulatory/Compliance
  • Operational Feasibility

A resolution call or document review meeting is typically organized to align on disputed comments and finalize resolutions.

All resolutions must be documented to maintain an audit trail and support GMP documentation principles.

Stage 4: Medical and Regulatory Review

Once functional comments are resolved, the protocol is sent for higher-level review:

  • Medical Review: Ensures scientific validity, safety measures, and consistency with therapeutic guidelines
  • Regulatory Review: Checks for compliance with global and local regulatory requirements, including Stability Studies data if applicable

This review ensures readiness for submission to health authorities like EMA, CDSCO, or Health Canada.

Stage 5: Quality Control (QC) Review

The Quality team performs a detailed document-level QC, including:

  • Grammatical accuracy and style consistency
  • Cross-reference verification (e.g., sections, annexes)
  • Protocol version number and date correctness
  • Removal of draft watermarks or annotations

QC outcomes are documented, and necessary corrections are made before final sign-off.

Stage 6: Version Control and Document Sign-Off

Once QC is complete, the final protocol is assigned a unique version number. Each version must be archived in the document management system (DMS).

The document then goes through electronic or wet-ink approval by designated signatories:

  • Clinical Head
  • Regulatory Affairs Head
  • Medical Affairs
  • Sponsor or CRO Representative
  • Legal or Compliance (if required)

Signatures are captured in compliance with 21 CFR Part 11 for electronic records.

Stage 7: Final Approval and Archival

Once all signatories approve, the protocol is considered final and becomes the source of truth for the clinical trial conduct.

  • Upload final PDF to the electronic trial master file (eTMF)
  • Distribute to study sites, IRBs, and regulatory agencies
  • Update validation master plans and supporting documentation if required

Changes post-approval require formal protocol amendments, tracked with justification and version history.

Best Practices for Protocol Review Workflows:

  1. Define a written SOP outlining workflow timelines and reviewer roles
  2. Use shared platforms like Veeva Vault, Wingspan, or SharePoint
  3. Set clear deadlines and automated reminders for reviewers
  4. Maintain a comment matrix for transparency and accountability
  5. Conduct a final checklist audit before submission

These practices minimize the risk of delays, rework, and regulatory objections.

Conclusion:

An effective review and approval workflow for protocol documents enhances study quality, accelerates submissions, and ensures global regulatory compliance. By involving cross-functional stakeholders, using structured tools, and adhering to document control standards, pharma and clinical trial professionals can execute trials with precision and confidence.

Ensure you have SOPs in place and train your team on protocol lifecycle management. A structured workflow not only saves time but ensures the scientific and ethical integrity of your clinical research.

]]>